Recent advances in nanocarriers for pancreatic cancer therapy

Shalini Preethi, V. Sindhu, Karthik Sambath, Arun Reddy Ravula, Geetha Palani, Sivakumar Vijayaraghavalu, Shanmuga Sundari, Venkatesan Perumal

Research output: Chapter in Book/Report/Conference proceedingChapter


A set of disorders known collectively as cancers are connected to unnatural cell proliferation. Without any intervention, the illness could worsen, resulting in premature death. A lethal malignant tumor is threatened invasion. Pancreatic cancer (PC) is more frequently found in men and elder persons (60-85 years old). Young individuals are recently being identified with PC more frequently. Being one of the deadliest tumors, it has no earliest symptoms and it can quickly infect nearby tissues and organs. Despite significant advancements in the struggle against the disease, continued, intense efforts are made to promote early detection and treatments. Nanomaterials have gained more attentiveness recently for PC diagnosis and treatment. The most recent information about PC risk, diagnostics, and therapy, as well as the role of polymeric NPs (PNPs) in PC treatment and diagnosis are discussed in this chapter. PNPs synthesis and characterization techniques are also discussed. PNPs have the capability to give improvements in early diagnosis, therapeutic monitoring, and image-guided surgery. Drug delivery using PNP increases tumor targeting penetration, targeted and specific drug delivery, and antitumor activity, enhances the stability and biological uptake of the drugs, and reduces cytotoxicity.

Original languageEnglish (US)
Title of host publicationRecent Advances in Nanocarriers for Pancreatic Cancer Therapy
Number of pages43
ISBN (Electronic)9780443191428
ISBN (Print)9780443152887
StatePublished - Jan 1 2023

All Science Journal Classification (ASJC) codes

  • General Computer Science


  • Cancer
  • antitumor activity
  • diagnosis
  • pancreatic cancer
  • polymeric NPs
  • treatment


Dive into the research topics of 'Recent advances in nanocarriers for pancreatic cancer therapy'. Together they form a unique fingerprint.

Cite this